NCT00739453View on ClinicalTrials.gov

A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)

PHASE1CompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

October 23, 2008

Primary Completion Date

March 3, 2012

Study Completion Date

March 3, 2012

Conditions
Advanced Solid Tumors
Interventions
DRUG

OSI-906

administered orally

DRUG

erlotinib

administered orally

Trial Locations (4)

21231

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore

48201

Hudson-Webber Cancer Research Center, Karmanos Cancer Institute, Detroit

80045

University of Colorado Health Science Center, Aurora

OX3 7LJ

University of Oxford Department of Medical Oncology, Oxford

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY

NCT00739453 - A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®) | Biotech Hunter | Biotech Hunter